Literature DB >> 23801140

Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin A : a case report.

Morihiro Inoue1, Mayuka Ankou, Jiang Hua, Yasunobu Iwaki, Masao Hagihara, Yasunori Ota.   

Abstract

A 49-year-old woman with severe thrombocytopenia was admitted after an episode of syncope. She also had anemia, fever, pleural effusion and ascites, and multiple lymphadenopathies subsequently appeared. Her bone marrow showed increased megakaryocytes with mild fibrosis, whereas her lymph nodes lacked histologically specific findings. Her presentation was not consistent with multicentric Castleman's disease, angioimmunoblastic T-cell lymphoma, systemic lupus erhythematosus or any other well-recognized entities. Her clinical features were, however, thought to be compatible with TAFRO (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly) syndrome. Corticosteroid therapy induced a partial remission of fever and systemic fluid retention, but thrombocytopenia persisted. After additional immunosuppressive therapy with cyclosporin A, her symptoms showed full resolution. [J Clin Exp Hematop 53(1) : 95-99, 2013].

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23801140     DOI: 10.3960/jslrt.53.95

Source DB:  PubMed          Journal:  J Clin Exp Hematop        ISSN: 1346-4280


  28 in total

1.  International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; Thomas S Uldrick; Adam Bagg; Dale Frank; David Wu; Gordan Srkalovic; David Simpson; Amy Y Liu; David Menke; Shanmuganathan Chandrakasan; Mary Jo Lechowicz; Raymond S M Wong; Sheila Pierson; Michele Paessler; Jean-François Rossi; Makoto Ide; Jason Ruth; Michael Croglio; Alexander Suarez; Vera Krymskaya; Amy Chadburn; Gisele Colleoni; Sunita Nasta; Raj Jayanthan; Christopher S Nabel; Corey Casper; Angela Dispenzieri; Alexander Fosså; Dermot Kelleher; Razelle Kurzrock; Peter Voorhees; Ahmet Dogan; Kazuyuki Yoshizaki; Frits van Rhee; Eric Oksenhendler; Elaine S Jaffe; Kojo S J Elenitoba-Johnson; Megan S Lim
Journal:  Blood       Date:  2017-01-13       Impact factor: 22.113

2.  Aggressive TAFRO syndrome with reversible cardiomyopathy successfully treated with combination chemotherapy.

Authors:  Shunichiro Yasuda; Keisuke Tanaka; Ayako Ichikawa; Ken Watanabe; Emi Uchida; Masahide Yamamoto; Kouhei Yamamoto; Daisuke Mizuchi; Osamu Miura; Tetsuya Fukuda
Journal:  Int J Hematol       Date:  2016-05-31       Impact factor: 2.490

Review 3.  Multicentric Castleman disease: Where are we now?

Authors:  Hao-Wei Wang; Stefania Pittaluga; Elaine S Jaffe
Journal:  Semin Diagn Pathol       Date:  2016-05-16       Impact factor: 3.464

4.  Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version.

Authors:  Yasufumi Masaki; Hiroshi Kawabata; Kazue Takai; Masaru Kojima; Norifumi Tsukamoto; Yasuhito Ishigaki; Nozomu Kurose; Makoto Ide; Jun Murakami; Kenji Nara; Hiroshi Yamamoto; Yoko Ozawa; Hidekazu Takahashi; Katsuhiro Miura; Tsutomu Miyauchi; Shinichirou Yoshida; Akihito Momoi; Nobuyasu Awano; Soichiro Ikushima; Yasunori Ohta; Natsue Furuta; Shino Fujimoto; Haruka Kawanami; Tomoyuki Sakai; Takafumi Kawanami; Yoshimasa Fujita; Toshihiro Fukushima; Shigeo Nakamura; Tomohiro Kinoshita; Sadao Aoki
Journal:  Int J Hematol       Date:  2016-03-18       Impact factor: 2.490

5.  How we manage idiopathic multicentric Castleman disease.

Authors:  Joshua D Brandstadter; David C Fajgenbaum
Journal:  Clin Adv Hematol Oncol       Date:  2022-09

6.  Thrombotic microangiopathy on kidney biopsy in a patient with TAFRO syndrome.

Authors:  Toshikazu Ozeki; Masashi Tsuji; Junichiro Yamamoto; Chisato Shigematsu; Shoichi Maruyama
Journal:  CEN Case Rep       Date:  2018-05-15

7.  Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome.

Authors:  Shotaro Tatekawa; Koji Umemura; Ryuichi Fukuyama; Akio Kohno; Masafumi Taniwaki; Junya Kuroda; Yoshihisa Morishita
Journal:  Clin Case Rep       Date:  2015-04-22

8.  Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report.

Authors:  Silvia Tedesco; Laura Postacchini; Lucia Manfredi; Gaia Goteri; Michele M Luchetti; Antonella Festa; Armando Gabrielli; Giovanni Pomponio
Journal:  Exp Hematol Oncol       Date:  2015-01-14

Review 9.  Idiopathic multicentric Castleman's disease: a systematic literature review.

Authors:  Amy Y Liu; Christopher S Nabel; Brian S Finkelman; Jason R Ruth; Razelle Kurzrock; Frits van Rhee; Vera P Krymskaya; Dermot Kelleher; Arthur H Rubenstein; David C Fajgenbaum
Journal:  Lancet Haematol       Date:  2016-03-17       Impact factor: 18.959

10.  International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.

Authors:  Frits van Rhee; Peter Voorhees; Angela Dispenzieri; Alexander Fosså; Gordan Srkalovic; Makoto Ide; Nikhil Munshi; Stephen Schey; Matthew Streetly; Sheila K Pierson; Helen L Partridge; Sudipto Mukherjee; Dustin Shilling; Katie Stone; Amy Greenway; Jason Ruth; Mary Jo Lechowicz; Shanmuganathan Chandrakasan; Raj Jayanthan; Elaine S Jaffe; Heather Leitch; Naveen Pemmaraju; Amy Chadburn; Megan S Lim; Kojo S Elenitoba-Johnson; Vera Krymskaya; Aaron Goodman; Christian Hoffmann; Pier Luigi Zinzani; Simone Ferrero; Louis Terriou; Yasuharu Sato; David Simpson; Raymond Wong; Jean-Francois Rossi; Sunita Nasta; Kazuyuki Yoshizaki; Razelle Kurzrock; Thomas S Uldrick; Corey Casper; Eric Oksenhendler; David C Fajgenbaum
Journal:  Blood       Date:  2018-09-04       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.